Alkahest

About Alkahest

Alkahest is a clinical stage biopharmaceutical company focused on developing transformative therapies for neurodegenerative and age-related diseases. The company leverages a deep understanding of the plasma proteome—the complete set of proteins in plasma—to create groundbreaking treatments that can halt or reverse the harmful effects of aging. Alkahest's unique approach targets specific chronokines, proteins that change with age, to modulate a wide range of age-related disease mechanisms with precision.

Operating in the biopharmaceutical sector, Alkahest primarily serves patients suffering from conditions like Age-related Macular Degeneration (AMD) and other neurodegenerative diseases. The company operates on a business-to-business (B2B) model, partnering with larger pharmaceutical companies for the development and commercialization of its therapies. Revenue is generated through licensing agreements, milestone payments, and royalties from these partnerships.

In 2020, Alkahest was acquired by Grifols, a leading global producer of plasma-derived medicines, for $146 million. This acquisition has further strengthened Alkahest's capabilities and resources in the development of innovative therapies.